摘要
目的:研究氟伐他汀联合阿罗洛尔对冠心病(CHD)并发心力衰竭(HF)患者的疗效及对血清生长分化因子15(GDF-15)、中性粒细胞明胶酶相关脂质运载蛋白(NGAL)水平的影响。方法:选择我院心内科于2013年5月至2015年5月期间收治的140例CHD+HF患者。按照随机数字表法,患者被随机均分为阿罗洛尔组和联合治疗组(在阿罗洛尔组基础上加用氟伐他汀),疗程为3个月。对比两组治疗效果、治疗前后左室舒张末内径(LVEDd)、舒张末室间隔厚度(IVSTd)、左室射血分数(LVEF)、平均动脉压(MAP)、心脏指数(CI)、每博指数(SI)、每博输出量(SV)、血清GDF-15和NGAL水平。结果:与阿罗洛尔组比较,联合治疗组治疗后LVEF[(45.31±6.73)%比(72.64±7.29)%]、MAP[(59.34±6.93)mmHg比(75.61±7.24)mmHg]、CI[(2.66±1.31)L/min^2比(3.12±1.37)L/min^2]、SI[(27.15±4.37)ml/m^2比(49.81±5.79)ml/m^2]和SV[(60.99±5.13)ml比(71.24±5.94)ml]升高更显著,IVSTd[(13.51±3.17)mm比(11.27±7.26)mm]、血清GDF-15[(1153.4±153.7)ng/L比(923.8±81.4)ng/L]和NGAL[(112.52±61.49)μg/L比(78.14±35.74)μg/L]水平降低更显著(P<0.05或<0.01)。联合治疗组治疗总有效率显著高于阿罗洛尔组(87.14%比74.29%),P=0.007。结论:氟伐他汀联合阿罗洛尔能够有效改善冠心病并发心力衰竭患者的心功能,显著降低血清GDF-15和NGAL水平,改善患者的预后,值得推广。
Objective： To study therapeutic effect and influence of fluvastatin combined arotinolol on serum levels of growth differentiation factor 15 （GDF-15） and neutrophil gelatinase associated lipocalin （NGAL） in patients with coronary heart disease （CHD） complicated heart failure （HF）. Methods： A total of 140 CHD ± HF patients, who were treated in our department of cardiology from May 2013 to May 2015, were selected. According to random number table, patients were randomly and equally divided into arotinolol group and combined treatment group （received fluvastatin based on arotinolol group）, both groups were treated for three months. Therapeutic effect, left ventricular end-diastolic dimension （LVEDd）, end-diastolic interventricular septal thickness （IVSTd）, left ventricu- lar ejection fraction （LVEF）, mean arterial pressure （MAP）, cardiac index （CI）, stroke index （SI）, stroke volume （SV）, serum levels of GDF-15 and NGAL before and after treatment were compared between two groups. Results： Compared with arotinolol group after treatment, there were significant rise in LVEF F （45.31 ± 6.73）% vs. （72.64 ±7.29）%1, MAP[ （59.34±6.93） mmHgvs. （75.61±7.24） mmHg], CI [ （2.66±1.31） L/min2 vs. （3.12± 1.37） L/min2], SI [ （27.15 ± 4. 37） ml/m2 vs. （49.81 ± 5.79） ml/m27 and SV r （60.99 ± 5.13） ml vs. （71.24 ± 5.94） ml], and significant reductions in IVSTd [ （13.51 ± 3.17） mm vs. （11.27 ± 7.26） mm], serum levels of GDF-15 [ （1153.4± 153.7） ng/L vs. （923.8 ± 81.4） ng/L] and NGAL [ （112.52 ± 61.49） μg/L vs. （78.14 ± 35.74） μg/L] in combined treatment group （P〈0.05 or 〈0.01）. Total effective rate of combined treatment group was significantly higher than that of arotinolol group （87.14% vs. 74.29%）, P = 0. 007. Conclusion： Fluvastatin combined arotinolol can effectively improve heart function, significantly reduce serum GDF-15 and NGAL levels,and improve prognosis in CHD ± HF patients, which is worth extending.
出处
《心血管康复医学杂志》
CAS
2018年第1期64-68,共5页
Chinese Journal of Cardiovascular Rehabilitation Medicine
基金
2012年度衡水市科学技术研究与发展计划项目(12015Z)~~
关键词
冠心病
心力衰竭
生长分化因子15
氟伐他汀
阿罗洛尔
Coronary disease
Heart failure
Growth differentiation factor 15
Fluvastatin
Arotinolol
